NeuralCure AI Announces Partnership with Life Imaging FLA

This partnership immediately positions NeuralCure AI for rapid, real-world application, further solidifying its role as a pioneer in AI-powered healthcare solutions. Unlike traditional AI models that provide generalized insights, NeuralCure AI creates patient-specific digital twins and runs constant treatment simulations, helping physicians make more informed, data-driven decisions without replacing clinical judgment.

Kabooxa: New Cutting-Edge Software Assistant Bridges Gap Between AI and Monetization

All around the world, the proliferation of AI tools has decision-makers and business leaders asking each other “What are our needs and how can we use AI to meet them?” The engineers at Kabooxa have solved this contemporary business conundrum by asking another question: “What about an enterprise AI engine that you can leverage to boost performance and ROI?”

Jupiter Endovascular Appoints Fred Ong as CFO

Fred Ong brings more than 30 years of experience in building and growing venture capital-backed healthcare technology companies to his role at Jupiter Endovascular, including playing key roles in fundraising, corporate strategy, operational growth, revenue scale, and M&A exits.

Tom Arnold Appointed CEO of ViCentra

Tom Arnold brings almost 25 years of extensive leadership experience in diabetes and medical technology and has a strong track record in spearheading commercialization initiatives, business strategy, and product launches for leading medical device companies. He has held key leadership roles at Medtronic, PROCEPT BioRobotics, Boston Scientific, and Sorin Group.

EPO Grants Key CRISPR Patent to ERS Genomics CVC Portfolio

John E Milad, CEO of ERS Genomics, said: “The EPO’s decision to grant EP 4 289 948 with broad claims reinforces CVC’s leadership position in CRISPR IP in Europe and validates our strategic decision to self-revoke two legacy CRISPR/Cas9 patents. This decision provides our 150+ licensees with greater confidence in their rights, while maintaining CVC’s established patent leadership in Europe.”